2021
DOI: 10.5935/2526-8732.20210003
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacogenomic tests in Oncology - finding the right dose

Abstract: A pharmacogenetics/genomics (PGx) anticancer drug testing program is being developed by Kurtz and his group at the Brazilian National Cancer Institute (INCA). Drug -gene pairs were selected for PGx testing based on the presence of clinically validated PGx associations and the availability of international guidelines with PGx-informed dosing recommendations. Fluoropyrimidines-DPYD, irinotecan-UGT1A1 and thiopurines-TPMT/NUDT15 were initially included. The current estimation of anticancer therapy doses usually d… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 15 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?